EUVIMEDEUVIMED entdecken
Kohortenstudie

Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study

Rishi Chowdhary, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Megh Patel, Tanisha Sehgal, Kirti Arora, Rahul Chowdhary, Varun Mehta, Akash Batta iD, Omesh Goyal

Hepatology Research · 2026-06 · 56 (6) · 1026-1046

DOI: 10.1111/hepr.70158 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Hepatology Research, online erschienen am 19.03.2026. Verfasst von Rishi Chowdhary und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Lean metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized; however, its long‐term hepatic risk relative to obese MASLD remains elusive. This study evaluated differential risk of progressive hepatic outcomes and identified predictors of adverse outcomes within the lean phenotype.

Methods

A large, multicenter retrospective cohort study was conducted using the TriNetX Global Health Research Network, including adults with noncirrhotic MASLD between 2010 and 2024. Lean MASLD was defined as the body mass index (BMI) < 25 kg/m 2 . Primary analyses compared lean versus nonlean MASLD (BMI ≥ 25 kg/m 2 ), with a prespecified secondary analysis comparing lean versus obese MASLD (BMI ≥ 30 kg/m 2 ), excluding overweight individuals. Outcomes included incident fibrosis, cirrhosis, portal hypertension and related complications, hepatocellular carcinoma (HCC), liver transplantation, and all‐cause mortality over 3‐year, 5‐year, and 10‐year follow‐up. Propensity score matching and multivariable Cox regression were applied.

Results

Among 1,130,297 patients with MASLD, 229,084 had lean MASLD. After matching, lean MASLD was associated with consistently higher odds of fibrosis, cirrhosis, portal hypertensive complications, HCC, liver transplantation, and mortality compared with nonlean, overweight, and obese MASLD across all time horizons (all p < 0.001). Within the lean MASLD cohort, those with older age, diabetes, hypoalbuminemia, thrombocytopenia, and elevated aspartate aminotransferase independently predicted adverse hepatic outcomes.

Conclusions

Lean MASLD is associated with substantial long‐term hepatic morbidity and mortality. Currently, obesity‐centered paradigms guide MASLD screening and risk stratification. Thus, efforts should be made to ensure that lean individuals with MASLD are not systematically under‐screened or under‐surveilled for progressive liver disease as they carry a higher risk of worsening.

Schlagwörter

Stichwörter der Autor:innen

body mass indexhepatocellular carcinomalean MASLDliver fibrosismortalityobesityrace and ethnicity

Autor:innen und Institutionen

  • Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA.
  • Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Internal Medicine, B. J. Medical College, Gujrat, India.
  • Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
  • Department of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, Ohio, USA.

ORCID-Profile: Akash Batta

Zitieren

APA

Chowdhary, R., Goyal, M. K., Vuthaluru, A. R., Patel, M., Sehgal, T., Arora, K., Chowdhary, R., Mehta, V., Batta, A., & Goyal, O. (2026). Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study. Hepatology Research, 56(6), 1026-1046. https://doi.org/10.1111/hepr.70158

Vancouver

Chowdhary R, Goyal MK, Vuthaluru AR, Patel M, Sehgal T, Arora K, et al. Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study. Hepatology Research. 2026;56(6):1026-1046. doi:10.1111/hepr.70158

BibTeX
@article{Chowdhary2026,
  author = {Chowdhary, Rishi and Goyal, Manjeet Kumar and Vuthaluru, Ashita Rukmini and Patel, Megh and Sehgal, Tanisha and Arora, Kirti and Chowdhary, Rahul and Mehta, Varun and Batta, Akash and Goyal, Omesh},
  title = {Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {6},
  pages = {1026--1046},
  doi = {10.1111/hepr.70158}
}
Kostenlos starten →